Endocannabinoids travel in tiny cell-derived particles during COVID-19 and increase with disease severity
Endocannabinoids were significantly enriched in extracellular vesicles compared to plasma in COVID-19 patients, with concentrations increasing alongside disease severity.
Quick Facts
What This Study Found
Except for anandamide, endocannabinoid concentrations (2-AG, SEA, PEA, OEA) were significantly higher in extracellular vesicles than in plasma, and these EV-endocannabinoid levels increased with COVID-19 severity. MicroRNA analysis revealed regulatory networks that appeared to fine-tune endocannabinoid signaling in immune cells.
Key Numbers
Five endocannabinoids measured: anandamide, 2-AG, SEA, PEA, and OEA. Four of five were significantly enriched in EVs versus plasma. Steroid hormones (cortisol, testosterone) showed no EV enrichment, suggesting specificity for lipophilic signaling molecules.
How They Did This
Researchers measured five endocannabinoids in both extracellular vesicles and plasma from COVID-19 patients of varying severity. RNA sequencing of EV-derived microRNAs and blood cell mRNA was used to construct signaling networks connecting endocannabinoid transport to immune cell regulation.
Why This Research Matters
This study suggests the body uses extracellular vesicles as a delivery system for endocannabinoids during infection, and that this system scales up during severe illness. Understanding this transport mechanism could inform future strategies for modulating inflammation.
The Bigger Picture
The endocannabinoid system plays a role in immune regulation, but how these lipophilic molecules travel through the bloodstream has been unclear. This finding that EVs serve as transport vehicles opens new questions about how the body coordinates endocannabinoid-based immune responses.
What This Study Doesn't Tell Us
This is an observational study that cannot determine whether elevated EV-endocannabinoid levels are protective or harmful during COVID-19. Sample sizes were not specified in the abstract. The regulatory networks are inferred from correlation, not causation.
Questions This Raises
- ?Are elevated EV-endocannabinoid levels a protective response or a marker of disease progression?
- ?Could therapeutic manipulation of this transport system modulate inflammation in severe infections?
- ?Do other inflammatory conditions show similar EV-endocannabinoid patterns?
Trust & Context
- Key Stat:
- 4 of 5 endocannabinoids significantly enriched in extracellular vesicles vs. plasma
- Evidence Grade:
- This is a preliminary observational study identifying a novel transport mechanism. While the finding is intriguing, the clinical significance remains unclear and the regulatory networks are correlational.
- Study Age:
- Published in 2024 using data from COVID-19 patients.
- Original Title:
- Extracellular Vesicles and Endocannabinoid Signaling in Patients with COVID-19.
- Published In:
- Cannabis and cannabinoid research, 9(5), 1326-1338 (2024)
- Authors:
- Brandes, Florian, Keiler, Annekathrin M, Kirchner, Benedikt, Borrmann, Melanie, Billaud, Jean-Noël, Reithmair, Marlene, Klein, Matthias, Campolongo, Patrizia, Thieme, Detlef, Pfaffl, Michael W, Schelling, Gustav, Meidert, Agnes S
- Database ID:
- RTHC-05156
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What are extracellular vesicles?
Small lipid-membrane-covered particles released by cells that carry RNA, lipids, and proteins. They function as intercellular messengers, transporting signaling molecules from one cell to another.
Why were endocannabinoid levels higher with more severe COVID?
The study observed this pattern but the reason is not yet clear. It could reflect the body mounting a larger anti-inflammatory response, or it could be a consequence of widespread tissue damage during severe infection.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05156APA
Brandes, Florian; Keiler, Annekathrin M; Kirchner, Benedikt; Borrmann, Melanie; Billaud, Jean-Noël; Reithmair, Marlene; Klein, Matthias; Campolongo, Patrizia; Thieme, Detlef; Pfaffl, Michael W; Schelling, Gustav; Meidert, Agnes S. (2024). Extracellular Vesicles and Endocannabinoid Signaling in Patients with COVID-19.. Cannabis and cannabinoid research, 9(5), 1326-1338. https://doi.org/10.1089/can.2023.0040
MLA
Brandes, Florian, et al. "Extracellular Vesicles and Endocannabinoid Signaling in Patients with COVID-19.." Cannabis and cannabinoid research, 2024. https://doi.org/10.1089/can.2023.0040
RethinkTHC
RethinkTHC Research Database. "Extracellular Vesicles and Endocannabinoid Signaling in Pati..." RTHC-05156. Retrieved from https://rethinkthc.com/research/brandes-2024-extracellular-vesicles-and-endocannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.